McKesson stock stands at EUR 837.20 with a USD 999.00 52-week high

Published on 10/09/2026 at 19:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock was EUR 837.20 on October 9, 2026 versus EUR 829.80. NYSE MCK was USD 937.62 against a USD 999.00 high.

Key points in brief

McKesson stock stood at EUR 837.20 at Lang & Schwarz on October 9, 2026 at 7:22 p.m. CEST, up 0.89 percent from EUR 829.80.
The primary NYSE quote was USD 937.62, while the 52-week high was USD 999.00.
Market capitalization was USD 109.8 billion and the price-to-earnings ratio was 25.06.
Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00 on October 7, 2026.
McKesson is scheduled to report second-quarter fiscal 2027 results on November 4, 2026.

3D-Render eines modernen Glas-Bürogebäudes mit Grünanlage und Vorplatz — Architektur-Render eines modernen Hauptsitz-Gebäudes symbolisiert McKesson Corporation ISIN US58155Q1031 im Gesundheitssektor mit großer Glasfassade, Illustration mit AI erstellt.

McKesson stock (ISIN US58155Q1031) stood at EUR 837.20 at Lang & Schwarz on October 9, 2026 at 7:22 p.m. CEST, up 0.89 percent versus the prior close of EUR 829.80. The euro quote was in after-hours trading from a German investor perspective, while the primary listing remained on the NYSE.

Price sits below yearly high

The primary-market quote for McKesson was USD 937.62 at 1:25 p.m. ET on October 9, 2026. The quote was 6.15 percent below the USD 999.00 52-week high and 29.56 percent above the USD 723.68 52-week low.

Global Banking and Finance Review identifies McKesson as MCK on the US listing under ISIN US58155Q1031 and classifies the company in Health Care. That listing context keeps the euro quote separate from the USD price used for the 52-week comparison.

Valuation and analyst targets

McKesson had a market capitalization of USD 109.8 billion and a price-to-earnings ratio of 25.06 on October 9, 2026. The current quote therefore places valuation alongside a company whose scale remains much larger than either peer in the comparison below.

According to MarketBeat on October 7, 2026, Leerink Partners raised its McKesson target from USD 1,030.00 to USD 1,070.00 and maintained an Outperform rating. The new target lies 14.12 percent above the USD 937.62 primary-market quote.

MarketBeat lists 14 Buy ratings and four Hold ratings among 18 analysts, with an average target of USD 973.19. That consensus target lies 3.79 percent above USD 937.62, a narrower gap than the Leerink Partners target.

Comparison with peers

October 9, 2026 values:

McKesson: plus 0.89 percent, P/E 25.06, market capitalization USD 109.8 billion
Cardinal Health (NYSE, USD): minus 0.70 percent, P/E 32.82, market capitalization USD 55.6 billion
Cencora (NYSE, USD): plus 0.47 percent, P/E 23.98, market capitalization USD 62.8 billion

Next reporting date is November 4

McKesson's next scheduled reporting event is its second-quarter fiscal 2027 earnings call on November 4, 2026, according to McKesson Corporation in its October 1, 2026 release. The date gives the market a defined checkpoint for the next update on earnings and guidance.

After-hours quote stays in view

For German investors, the key distinction is the venue and currency: EUR 837.20 was the Lang & Schwarz quote, while USD 937.62 was the contemporaneous NYSE quote. The euro price rose 0.89 percent against the EUR 829.80 Lang & Schwarz prior close, a smaller move than the stock's distance from its USD 999.00 yearly high.

Market context: Market report S&P 500.